Close
Almac
Achema middle east

Berry Global Underlines Its Commitment to South East Asia Region

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.
- Advertisement -

Berry Global will demonstrate its commitment to delivering innovative, patient-centric packaging, dispensing solutions, and drug delivery devices for India and the South Asia region on the company’s stand at this year’s CPHI India exhibition.

Berry will showcase a wide range of products from its extensive portfolio, including bottles and caps, ophthalmic solutions, nasal and throat sprays, vials, dry powder inhalers (DPIs), and pressurized metered dose inhalers (pMDIs). Among these products will be the company’s latest advanced solutions for enhanced usability and administration safety, next generation digitalisation for medical devices and primary packaging, and circular design.

Many of the innovative products being shared at CPHI are produced at the company’s new factory and Centre of Excellence in Bangalore, India. The new location has both created local jobs and improved regional and global access to advanced healthcare solutions, providing customers with the necessary volume to support the forecasted growth for Asia’s domestic healthcare market.

“The Asia market is hugely important to Berry, as is evidenced by our ongoing investment in the region,” said Ramprakash Rai, Sales Director at Berry Global. “Our participation at CPHI India therefore provides the ideal opportunity to show the breadth of our products adapted to this exponential market, as we help our customers to Do Better by Dosing Better.”

“In particular, these solutions underline our abilities in developing solutions that enhance the user experience, improve disease management, and minimise environmental impact. We look forward to discussing customers’ specific requirements during CPHI India”
Berry is recognised as one of the global leaders in pharmaceutical packaging and dispensing, with over 25 healthcare-focused, ISCC PLUS-certified sites worldwide that enable the company to offer international and localised support for customers of all sizes. The company provides bespoke and standard solutions to help customers meet their unique product requirements and sustainability objectives.

Latest stories

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »